Protalex to start Phase Ib trial of immune thrombocytopenia drug in France
With the approval, the company now intends to begin the PRTX-100-203 trial at several sites in France with patient enrollment expected to start by this year end. Furthermore,
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
The approval of PD-L1 IHC 22C3 pharmDx strengthens Dako’s portfolio of companion diagnostics and the company’s leadership position in developing and commercializing companion diagnostic products. Dako developed PD-L1
Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. Under FDA’s accelerated approval regulations, this
The SOLUTION clinical study is designed to evaluate the efficacy and safety of Sollpura, a microbial derived, biotech pancreatic enzyme replacement therapy (PERT), compared to an approved, porcine-derived,